nsfa 2013 - Prévention des Risques Vasculaires

Pour citer cet article : Farnier M et al., Diagnostic et traitement des hypercholestérolémies familiales (HF) chez l’adulte : recommandations
de la Nouvelle société française d’athérosclérose (NSFA), Presse Med (2013), http://dx.doi.org/10.1016/j.lpm.2013.01.053.
M Farnier, E Bruckert, C Boileau, M Krempf
conclusions and recommendations oft he
National Lipid Association Statin Safety
Assessment Task Force. Am J Cardiol 2006;
97:C89-94.
[81] Ge L, Wang J, Qi W, Miao HH, Cao J, Qu XY
et al. The cholesterol absorption inhibitor
ezetimibe acts by blocking the sterol-induced
internalization of NPC1L1. Cell Metab
2008;7:508-19.
[82] Pandor A, Ara RM, Tumur I, Wilkinson AJ,
Paisley S, Duenas A et al. Ezetimibe monotherapy
for cholesterol lowering in 2722 people:
systematic review and meta-analysis of
randomized controlled trials. J Intern Med
2009;265:568-80.
[83] Birjmohun RS, Hutten BA, Kastelein JJ, Stroes
ESG. Efficacy and safety of high-density
lipoprotein cholesterol-increasing coumpounds.
A meta-analysis of randomized
controlled trials. J Am Coll Cardiol 2005;
45:185-97.
[84] Huijgen R, Kindt I, Verhoeven SBJ, Sijbrands
EJ, Vissers MN, Kastelein JJ et al. Two years
after molecular diagnosis of familial hypercholesterolemia:
majority on cholesterollowering
treatment but a minority reaches
treatment goal. Plos One 2010;5:e9220
([on line]).
[85] Pijlman AH, Huijgen R, Verhagen SN, Imholz
BP, Liem AH, Kastelein JJ et al. Evaluation of
cholesterol lowering treatment of patients
with familial hypercholesterolemia: a large
cross-sectional study in The Netherlands.
Atherosclerosis 2010;209:189-94.
[86] Stein E, Stender S, Mata P, Sager P,
Ponsonnet D, Melani L et al. Achieving
lipoprotein goals in patients at high risk with
severe hypercholesterolemia: efficacy and
safety of ezetimibe co-administered with
atorvastatin. Am Heart J 2004;148:447-55.
[87] Hamilton-Craig I, Kostner K, Colquhoun D,
Woodhouse S. Combination therapy of statin
and ezetimibe for the treatment of familial
hypercholesterolemia. Vasc Health Risk
Manag 2010;6:1023-37.
[88] Huijgen R, Abbink EJ, Bruckert E, Stalenhoef
AF, Imholz BP, Durrington BP et al. Colesevelam
added to combination therapy with a
statin and ezetimibe in patients with familial
hypercholesterolemia: a 12-week, multicenter,
randomised, double-blind, controlled
trial. Clin Ther 2010;32:615-25.
[89] Thompson GR, HEART-UK LDL Apheresis Working
Group. Recommendations for the use
of LDL apheresis. Atherosclerosis 2008;198:
247-55.
[90] Thompson GR, Catapano A, Saheb S, Atassi-
Dumont M, Barbir M, Eriksson M. Severe
hypercholesterolaemia: therapeutic goals
and eligibility criteria for LDL apheresis in
Europe. Curr Opin Lipidol 2010;21:492-8.
[91] Thompson GR, Barbir M, Davies D, Dobral P,
Gesinde M, Livingstone M et al. Efficacy
criteria and cholesterol targets for LDL
apheresis. Atherosclerosis 2010;208:317-21.
[92] Thompson GR. LDL apheresis. Atherosclerosis
2003;167:1-13.
[93] Marais AD, Naoumova RP, Firth JC, Penny C,
Neuwirth CK, Thompson GR. Decreased
production of low-density lipoprotein by
atorvastatin after apheresis in homozygous
familial hypercholesterolemia. J Lipid Res
1997;38:2071-8.
[94] Pfohl M, Naoumova RP, Klass C, Knisel W,
Jakober B, Risler T. Acute and chronic effects
on cholesterol biosynthesis of LDL-apheresis
with or without concomitant HMG-Co. A
reductase inhibitor therapy. J Lipid Res
1994;35:1946-55.
[95] Thompsen J, Thompson PD. A systematic
review of LDL apheresis in the treatment of
cardiovascular disease. Atherosclerosis
2006;189:31-8.
[96] Tatami R, Inove N, Itoh H, Kishino B, Koga N,
Nakashima Y et al. Regression of coronary
atherosclerosis by combined LDL-apheresis
and lipid-lowering drug therapy in patients
with familial hypercholesrolemia: a multicenter
study. The LARS Investigators. Atherosclerosis
1992;95:1-13.
[97] Waidner T, Franzen D, Voelker W, Ritter M,
Borberg H, Hombach V et al. The effect of
LDL apheresis on progression of coronary
artery disease in patients with familial
hypercholesterolemia. Results of a multicenter
LDL apheresis study. Clin Investig
1994;72:858-63.
[98] Schuff-Werner P, Gohike H, Bartmann U,
Baggio G, Corti MC, Dinsenbacher A et al. The
HELP-LDL-apheresis multicenter study, an
angiographically assesses trial on the role
of LDL-apheresis in the secondary prevention
of coronary heart disease II. Final evaluation
of the effect of regular treatment on LDL
cholesterol plasma concentration and the
course of coronary heart disease. Eur J Clin
Invest 1994;24:724-32.
[99] Thompson GR, Maher VM, Matthews, Kitano
Y, Neuwirth C, Shortt MB et al. Familial
hypercholesterolemia regression study: a
randomised trial of low-density-lipoprotein
apheresis. Lancet 1995;345:811-6.
[100]Kroon AA, Aengevaeren WR, van den Werf
T, Uijen GJ, Reiber JH, Bruschke AV et al. LDL-
Apheresis Atherosclerosis Regression Study
(LAARS). Effect of aggressive versus conventional
lipid lowering treatment of coronary
atherosclerosis. Circulation 1996;93:
1826-35.
[101]Mabuchi H, Koizumi J, Shimizu M, Kajinami K,
Miyamoto S, Ueda K et al. Long-term efficacy
of low-density lipoprotein apheresis on
coronary heart disease in familial hypercholesterolemia.
Hokuriku-FH-LDL-Apheresis
Study Group. Am J Cardiol 1998;82:1489-95.
[102]Ritcher WO, Donner MG, Hofling B, Schwandt
P. Long-term of low-density lipoprotein
apheresis on plasma lipoproteins and coronary
heart disease in native vessels and
coronary bypass in severe heterozygous
familial hypercholesterolemia. Metabolism
1998;47:863-8.
[103]Tamai O, Matsuoka H, Itabe Y, Kohno K,
Imaisumi T. Single LDL apheresis improves
endothelium-dependent vasodilation in hypercholesterolemia
humans. Circulation
1997;95:76-82.
[104]Igarashi K, Tsuji M, Nishimura M, Horimoto
M. Improvement of endothelium-dependent
coronary vasodilation after a single LDL
apheresis in patients with hypercholesterolemia.
J Clin Apher 2004;19:11-6.
[105]Sato M, Amano I. Changes in oxidative stress
and microcirculation by low-density lipoprotein
apheresis. Ther Apher Dial 2003;7:419-
24.
[106]Kobayashi K, Yamashita K, Tasaki H, Suzuka
H, Nihei S, Ozumi K et al. Evaluation of
improtved coronary flow velocity reserve
using transthoracic Doppler echocardiography
after single LDL apheresis. Ther Apher
Dial 2004;8:383-9.
[107]Choh SA, Choh NA, Rasool A, Yousuf R,
Qureshi U. Homozygous familial hypercholesterolemia.
J Pediatr Endocrinol Metab
2009;22:573-5.
[108]Morrisett JD, Vickers KC. Vascular calcification
in homozygote familial hypercholesterolemia.
Arterioscler Thromb Vasc Biol 2008;28:606-7.
[109]Naoumova RP, Thompson GR, Soutar AK.
Current management of severe homozygous
hypercholesterolaemias. Curr Opin Lipidol
2004;15:413-22.
[110]Goldammer A, Wiltschnig S, Heinz G, Jansen
M, Stulnig T, Hört WH et al. Atorvastatin in
low-density lipoprotein apheresis-treated patients
with homozygous and heterozygous
familial hypercholesterolemia. Metabolism
2002;51:976-80.
[111]Raal FJ, Pilcher GJ, Panz VR, van Deventer HE,
Brice BC, Blom DJ et al. Reduction in
mortality in subjects with homozygous
familial hypercholesterolemia associated
with advances in lipid-lowering therapy.
Circulation 2011;124:2202-7.
[112]Gagné C, Gaudet D, Bruckert E, Ezetimibe
Study Group. Efficacy and safety of ezetimibe
co-administered with atorvastatin or
simvastatin in patients with homozygous
familial hypercholesterolemia. Circulation
2002;105:2469-75.
[113]Hudgins LC, Kleinman B, Scheuer A, White S,
Gordon BR. Long-term safety and efficacy
of low-density lipoprotein apheresis in
childhood for homozygous familial hypercholesterolemia.
Am J Cardiol 2008;102:1199-
204.
[114]Raal FJ, Santos RD, Blom DJ, Marais AD,
Charng MJ, Cromwell WC et al. Mipomersen,
an apolipoprotein B synthesis inhibitor, for
lowering of LDL cholesterol concentrations in
patients with homozygous familial hypercholesterolaemia:
a randomised, double-blind,
p l a c e b o - c o n t r o l l e d t r i a l . L a n c e t
2010;375:998-1006.
20
tome // > n8/ > /